HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Some consider the small-cap and mid-cap - ''smid-cap'' - zone with market caps of $5 billion or less, a bit risky. They aren't wrong. However, if you can sustain some risk, some of the best biotech winners have historically been in this zone. If you shop carefully and can sustain a less conservative investment, there may be potential here to consider. That said, we've highlighted a few plays in this price range.
An oversold biotech with potential we like is Delcath Systems, Inc. (DCTH). Last September, the stock reached highs above $8 and is now sitting around support at $0.26. With potential liver cancer treatments in development (clinical trials) and a new licensing deal with a projected value of up to $45 million, there is an opportunity to consider here. With what we think is not much awareness among investors yet, it is possible that this stock has not reached a proper market valuation, and that's why we think you should start researching DCTH today.
An interventional oncology company focused on treating liver cancers with possible upside potential, Delcath Systems, Inc. (DCTH)(Market Cap: $3.16M, Share Price: $0.2831) is an interventional oncology company focused on treating liver cancers. The company has had some noteworthy developments this past year. They announced an amendment to their Phase 3 ocular melanoma liver metastases clinical trial, raised $7 million and were published in European Radiology among several other milestones. This is why we think the company could be one of the ones which could benefit if there is a biotech rally.
DCTH made news recently entering a licensing agreement for CHEMOSAT® commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac). The agreement has a projected value of up to $45 million over the first seven-year term and includes an optional five-year extension. Medac is a privately held, multi-national pharmaceutical company based in Hamburg area, Germany. Founded in 1970, medac specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases. The company has offices globally, worldwide partner agreements in over 90 countries, and approximately 1,200 employees.
This comes on the heels of an announcement about the independent Data Safety Monitoring Board (DSMB) of the Registration trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial) completed another pre-specified review of safety data for treated patients in the trial. This review was conducted on data collected from both the prior randomized protocol and the amended single-arm protocol for the FOCUS Trial. The DSMB again recommended continuation of the study without modification.
With more news on the horizon, there is potential for an event driven breakout basically any day.
Khiron Life Sciences, Corp. (KHRNF) (Market Cap: $153.981M, Share Price: $2.0759) announced that it has signed a binding letter of intent to establish a 50/50 joint venture with Dixie Brands Inc to introduce a full line of cannabis-infused products to the Latin American market. Per the details of the announcement, Dixie will also manufacture and distribute Khiron's Kuida® brand of cannabidiol (CBD)-based cosmeceuticals in the United States, targeting the growing Hispanic population.
Celldex Therapeutics, Inc. (CLDX) (Market Cap: $119.122M, Share Price: $0.6907) presented data from the Company's MerTK antibody program in a poster session recently at the Society for Immunotherapy of Cancer's (SITC) 33rdAnnual Meeting. MerTK is emerging as a promising target for cancer immunotherapy.
Geron Corporation (GERN) (Market Cap: $257.16M, Share Price: $1.38) announced positive results from its dose-finding pharmacokinetic ("PK") study - INS015-18-124 - evaluating proprietary formulation of epinephrine nasal spray for treating anaphylaxis, an acute, life-threatening allergic reaction. Data from the study showed that the candidate has a similar PK profile with Mylan's MYL EpiPen as well as Par Pharmaceuticals' Adrenalin (epinephrine injection).
INSYS Therapeutics, Inc. (INSY) (Market Cap: $294.851M, Share Price: $3.97), announced positive results from its dose-finding pharmacokinetic ("PK") study - INS015-18-124 - evaluating proprietary formulation of epinephrine nasal spray for treating anaphylaxis, an acute, life-threatening allergic reaction. Data from the study showed that the candidate has a similar PK profile with Mylan's MYL EpiPen as well as Par Pharmaceuticals' Adrenalin (epinephrine injection).
This article was written by Regal Consulting, LLC (''Regal Consulting''). Regal Consulting has agreed to a twelve-month term consulting agreement with DCTH dated 8/31/18. The agreement calls for $40,000 in cash, and 15,000 restricted 144 shares of DCTH per month. Issuer agreed to increase monthly cash payment in September to $120,000. All payments were made directly by Delcath Systems, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. DCTH was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communication, LLC
View source version on accesswire.com: